CD44 and neoplasm: Down-regulation of CD44 decreased the rate of onset and the magnitude of tumor burden in the animals, at all clinically-relevant sites including the brain, lung, liver and skeleton, indicating that CD44 does not preferentially select for the metastasis of breast cancer cells to specific tissues.